

HIGHLIGHTS OF PRESCRIBING INFORMATION

These highlights do not include all the information needed to use RAVICTI safely and effectively. See full prescribing information for RAVICTI.

RAVICTI® (glycerol phenylbutyrate) oral liquid
Initial U.S. Approval: 1996

INDICATIONS AND USAGE

RAVICTI (glycerol phenylbutyrate) is a nitrogen-binding agent indicated for chronic management of patients 2 years of age and older with urea cycle disorders (UCDs) who cannot be managed by dietary protein restriction and/or amino acid supplementation alone. RAVICTI must be used with dietary protein restriction and, in some cases, dietary supplements (e.g., essential amino acids, arginine, citrulline, protein-free calorie supplements). (1)
Limitations of Use:

- RAVICTI is not indicated for treatment of acute hyperammonemia in patients with UCDs. (1)
- Safety and efficacy for treatment of *N*-acetylglutamate synthase (NAGS) deficiency has not been established. (1)

DOSAGE AND ADMINISTRATION

RAVICTI should be prescribed by a physician experienced in management of UCDs. (2.1)

- Instruct patients to take with food and to administer directly into mouth via oral syringe or dosing cup.
- Total daily dosage is given in 3 equally divided dosages, rounded up to nearest 0.5 mL.
- Maximum daily dosage is 17.5 mL (19 g).
- Must be used with dietary protein restriction.

Switching From Sodium Phenylbutyrate to RAVICTI:

- Daily dosage of RAVICTI (mL) = daily dosage of sodium phenylbutyrate tablets (g) x 0.86. (2.2)
- Daily dosage of RAVICTI (mL) = daily dosage of sodium phenylbutyrate powder (g) x 0.81 (2.2)

Initial Dosage in Phenylbutyrate-Naïve Patients:

- Recommended dosage range is 4.5 to 11.2 mL/m²/day (5 to 12.4 g/m²/day). (2.3)
- For patients with some residual enzyme activity who are not adequately controlled with dietary restriction, recommended starting dose is 4.5 mL/m²/day. (2.3)
- Take into account patient's estimated urea synthetic capacity, dietary protein intake, and diet adherence. (2.3)

Dosage Modifications in Patients With Hepatic Impairment:

- Start dosage at lower end of range. (2.5, 8.6)

DOSAGE FORMS AND STRENGTHS

Oral liquid: 1.1 g/mL of glycerol phenylbutyrate. (3)

CONTRAINDICATIONS

- Patients less than 2 months of age. (4)
- Known hypersensitivity to phenylbutyrate. (4)

WARNINGS AND PRECAUTIONS

- **Neurotoxicity:** Phenylacetate (PAA), the active moiety of RAVICTI, may be toxic; reduce dosage for symptoms of neurotoxicity. (5.1)
- **Reduced Phenylbutyrate Absorption in Pancreatic Insufficiency or Intestinal Malabsorption:** Monitor ammonia levels closely. (5.2)

ADVERSE REACTIONS

Most common adverse reactions (≥10%) are: diarrhea, flatulence, and headache. (6)

To report SUSPECTED ADVERSE REACTIONS, contact Horizon Therapeutics at 1-855-823-7878 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

DRUG INTERACTIONS

- **Corticosteroids, valproic acid, or haloperidol:** May increase plasma ammonia level. Monitor ammonia levels closely. (7.1)
- **Probenecid:** May affect renal excretion of metabolites of RAVICTI, including phenylacetylglutamine (PAGN) and PAA. (7.2)
- **CYP3A4 Substrates with narrow therapeutic index (e.g., alfentanil, quinidine, cyclosporine):** RAVICTI may decrease exposure to the concomitant drug; monitor for decreased efficacy of the narrow therapeutic index drug (7.3)
- **Midazolam:** decreased exposure with concomitant use; monitor for suboptimal effect of midazolam if used concomitantly with RAVICTI. (7.3)

USE IN SPECIFIC POPULATIONS

- **Lactation:** Breastfeeding is not recommended. (8.2)

See 17 for PATIENT COUNSELING INFORMATION and Medication Guide.

Revised: 09/2016

FULL PRESCRIBING INFORMATION: CONTENTS*

| | |
|----------|---|
| 1 | INDICATIONS AND USAGE |
| 2 | DOSAGE AND ADMINISTRATION |
| 2.1 | Important Administration Instructions |
| 2.2 | Switching From Sodium Phenylbutyrate to RAVICTI |
| 2.3 | Initial Dosage in Phenylbutyrate-Naïve Patients |
| 2.4 | Dosage Adjustment and Monitoring |
| 2.5 | Dosage Modifications in Patients with Hepatic Impairment |
| 2.6 | Preparation for Nasogastric Tube or Gastrostomy Tube Administration |
| 3 | DOSAGE FORMS AND STRENGTHS |
| 4 | CONTRAINDICATIONS |
| 5 | WARNINGS AND PRECAUTIONS |
| 5.1 | Neurotoxicity |
| 5.2 | Reduced Phenylbutyrate Absorption in Pancreatic Insufficiency or Intestinal Malabsorption |
| 6 | ADVERSE REACTIONS |
| 6.1 | Clinical Trials Experience |
| 6.2 | Postmarketing Experience |
| 7 | DRUG INTERACTIONS |
| 7.1 | Potential for Other Drugs to Affect Ammonia |
| 7.2 | Potential for Other Drugs to Affect RAVICTI |
| 7.3 | Potential for RAVICTI to Affect Other Drugs |
| 8 | USE IN SPECIFIC POPULATIONS |
| 8.1 | Pregnancy |
| 8.2 | Lactation |
| 8.4 | Pediatric Use |

| | |
|-----------|--|
| 8.7 | Hepatic Impairment |
| 10 | OVERDOSAGE |
| 11 | DESCRIPTION |
| 12 | CLINICAL PHARMACOLOGY |
| 12.1 | Mechanism of Action |
| 12.2 | Pharmacodynamics |
| 12.3 | Pharmacokinetics |
| 13 | NONCLINICAL TOXICOLOGY |
| 13.1 | Carcinogenesis, Mutagenesis, Impairment of Fertility |
| 14 | CLINICAL STUDIES |
| 14.1 | Clinical Studies in Adult Patients with UCDs |
| 14.2 | Clinical Studies in Pediatric Patients with UCDs |
| 16 | HOW SUPPLIED/STORAGE AND HANDLING |
| 17 | PATIENT COUNSELING INFORMATION |

*Sections or subsections omitted from the full prescribing information are not listed.

FULL PRESCRIBING INFORMATION

1 INDICATIONS AND USAGE

RAVICTI is indicated for use as a nitrogen-binding agent for chronic management of patients 2 years of age and older with urea cycle disorders (UCDs) who cannot be managed by dietary protein restriction and/or amino acid supplementation alone. RAVICTI must be used with dietary protein restriction and, in some cases, dietary supplements (e.g., essential amino acids, arginine, citrulline, protein-free calorie supplements).

Limitations of Use:

- RAVICTI is not indicated for the treatment of acute hyperammonemia in patients with UCDs because more rapidly acting interventions are essential to reduce plasma ammonia levels.
- The safety and efficacy of RAVICTI for the treatment of *N*-acetylglutamate synthase (NAGS) deficiency has not been established.

2 DOSAGE AND ADMINISTRATION

2.1 Important Administration Instructions

RAVICTI should be prescribed by a physician experienced in the management of UCDs. Instruct patients to take RAVICTI with food and to administer directly into the mouth via oral syringe or dosing cup. See the instructions on the use of RAVICTI by nasogastric tube or g-tube [see *Dosage and Administration (2.6)*].

The recommended dosages for patients switching from sodium phenylbutyrate to RAVICTI and patients naïve to phenylbutyric acid are different [see *Dosage and Administration (2.2, 2.3)*]. For both subpopulations:

- Give RAVICTI in 3 equally divided dosages, each rounded up to the nearest 0.5 mL.
- The maximum total daily dosage is 17.5 mL (19 g).
- RAVICTI must be used with dietary protein restriction and, in some cases, dietary supplements (e.g., essential amino acids, arginine, citrulline, protein-free calorie supplements).

2.2 Switching From Sodium Phenylbutyrate to RAVICTI

Patients switching from sodium phenylbutyrate to RAVICTI should receive the dosage of RAVICTI that contains the same amount of phenylbutyric acid. The conversion is as follows:

Total daily dosage of RAVICTI (mL) = total daily dosage of sodium phenylbutyrate tablets (g) x 0.86

Total daily dosage of RAVICTI (mL) = total daily dosage of sodium phenylbutyrate powder (g) x 0.81

2.3 Initial Dosage in Phenylbutyrate-Naïve Patients

The recommended dosage range, based upon body surface area, in patients naïve to phenylbutyrate (PBA) is 4.5 to 11.2 mL/m²/day (5 to 12.4 g/m²/day). For patients with some residual enzyme activity who are not adequately controlled with protein restriction, the recommended starting dosage is 4.5 mL/m²/day.

In determining the starting dosage of RAVICTI in treatment-naïve patients, consider the patient's residual urea synthetic capacity, dietary protein requirements, and diet adherence. Dietary protein is approximately 16% nitrogen by weight. Given that approximately 47% of dietary nitrogen is excreted as waste and approximately 70% of an administered PBA dose will be converted to urinary phenylacetylglutamine (U-PAGN), an initial estimated RAVICTI dose for a 24-hour period is 0.6 mL RAVICTI per gram of dietary protein ingested per 24-hour period. The total daily dosage should not exceed 17.5 mL.

2.4 Dosage Adjustment and Monitoring

Adjustment Based on Plasma Ammonia: Adjust the RAVICTI dosage to produce a fasting plasma ammonia level that is less than half the upper limit of normal (ULN) according to age.

Adjustment Based on Urinary Phenylacetylglutamine: If available, U-PAGN measurements may be used to help guide RAVICTI dose adjustment. Each gram of U-PAGN excreted over 24 hours covers waste nitrogen generated from 1.4 grams of dietary protein. If U-PAGN excretion is insufficient to cover daily dietary protein intake and the fasting ammonia is greater than half the ULN, the RAVICTI dose should be adjusted upward. The amount of dose adjustment should factor in the amount of dietary protein that has not been covered, as indicated by the 24-h U-PAGN level and the estimated RAVICTI dose needed per gram of dietary protein ingested and the maximum total daily dosage (i.e., 17.5 mL).

Consider a patient's use of concomitant medications, such as probenecid, when making dosage adjustment decisions based on U-PAGN. Probenecid may result in a decrease of the urinary excretion of PAGN [*see Drug Interactions (7.2)*].

Adjustment Based on Plasma Phenylacetate: If available, measurements of the plasma phenylacetate (PAA) levels may be useful to guide dosing if symptoms of vomiting, nausea, headache, somnolence, confusion, or sleepiness are present in the absence of high ammonia or intercurrent illness. Ammonia levels must be monitored closely when changing the dose of RAVICTI. The ratio of PAA to PAGN in plasma may provide additional information to assist in dose adjustment decisions. In patients with a high PAA to PAGN ratio, a further increase in RAVICTI dose may not increase PAGN formation, even if plasma PAA concentrations are increased, due to saturation of the conjugation reaction. The PAA to PAGN ratio has been observed to be generally less than 1 in patients without significant PAA accumulation [*see Warnings and Precautions (5.1)*].

2.5 Dosage Modifications in Patients with Hepatic Impairment

For patients with moderate to severe hepatic impairment, the recommended starting dosage is at the lower end of the range [*see Warnings and Precautions (5.1), Use in Specific Populations (8.6)*].

2.6 Preparation for Nasogastric Tube or Gastrostomy Tube Administration

For patients who have a nasogastric tube or gastrostomy tube in place, administer RAVICTI as follows:

- Utilize an oral syringe to withdraw the prescribed dosage of RAVICTI from the bottle.
- Place the tip of the syringe into the tip of the gastrostomy/nasogastric tube.
- Utilizing the plunger of the syringe, administer RAVICTI into the tube.
- Flush once with 30 mL of water and allow the flush to drain.
- Flush a second time with an additional 30 mL of water to clear the tube.

3 DOSAGE FORMS AND STRENGTHS

Oral liquid: colorless to pale yellow, 1.1 g/mL of glycerol phenylbutyrate (delivers 1.02 g/mL of phenylbutyrate).

4 CONTRAINDICATIONS

RAVICTI is contraindicated in patients

- Less than 2 months of age. Pediatric patients less than 2 months of age may have immature pancreatic exocrine function, which could impair hydrolysis of RAVICTI, leading to impaired absorption of phenylbutyrate and hyperammonemia [*see Use in Specific Populations (8.4)*].
- With known hypersensitivity to phenylbutyrate. Signs of hypersensitivity include wheezing, dyspnea, coughing, hypotension, flushing, nausea, and rash.

5 WARNINGS AND PRECAUTIONS

5.1 Neurotoxicity

The major metabolite of RAVICTI, PAA, is associated with neurotoxicity. Signs and symptoms of PAA neurotoxicity, including somnolence, fatigue, lightheadedness, headache, dysgeusia, hypoacusis, disorientation, impaired memory, and exacerbation of preexisting neuropathy, were observed at plasma PAA concentrations of 500 micrograms/mL in a study of cancer patients who were administered IV PAA. In this study, adverse reactions were reversible.

In healthy subjects, after administration of 4 mL and 6 mL RAVICTI 3 times daily for 3 days, a dose-dependent increase in all-grade nervous system adverse reactions was observed, even at exposure levels of PAA less than 100 micrograms/mL.

In clinical trials in UCD patients who had been on sodium phenylbutyrate prior to administration of RAVICTI, peak PAA concentrations after dosing with RAVICTI ranged from 1.6 to 178 micrograms/mL (mean: 39 micrograms/mL) in adult patients and from 7 to 480 micrograms/mL (mean: 90 micrograms/mL) in pediatric patients. Some UCD patients experienced headache, fatigue, symptoms of peripheral neuropathy, seizures, tremor and/or dizziness. No correlation between PAA levels and neurotoxicity symptoms was identified but PAA levels were generally not measured at the time of neurotoxicity symptoms.

If symptoms of vomiting, nausea, headache, somnolence, or confusion, are present in the absence of high ammonia or other intercurrent illnesses, reduce the RAVICTI dosage.

5.2 Reduced Phenylbutyrate Absorption in Pancreatic Insufficiency or Intestinal Malabsorption

Exocrine pancreatic enzymes hydrolyze RAVICTI in the small intestine, separating the active moiety, phenylbutyrate, from glycerol. This process allows phenylbutyrate to be absorbed into the circulation. Low or absent pancreatic enzymes or intestinal disease resulting in fat malabsorption may result in reduced or absent digestion of RAVICTI and/or absorption of phenylbutyrate and reduced control of plasma ammonia. Monitor ammonia levels closely in patients with pancreatic insufficiency or intestinal malabsorption.

6 ADVERSE REACTIONS

6.1 Clinical Trials Experience

Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in clinical practice.

Assessment of adverse reactions was based on exposure of 45 adult patients (31 female and 14 male) with UCD subtype deficiencies of ornithine transcarbamylase (OTC, n=40), carbamyl phosphate synthetase (CPS, n=2), and argininosuccinate synthetase (ASS, n=1) in a randomized, double-blind, active-controlled (RAVICTI vs sodium phenylbutyrate), crossover, 4-week study (Study 1) that enrolled patients 18 years of age and older [*see Clinical Studies (14.1)*]. One of the 45 patients received only sodium phenylbutyrate prior to withdrawing on day 1 of the study due to an adverse reaction.

The most common adverse reactions (occurring in at least 10% of patients) reported during short-term treatment with RAVICTI were diarrhea, flatulence, and headache. Table 1 summarizes adverse reactions occurring in 2 or more patients treated with RAVICTI or sodium phenylbutyrate (incidence of at least 4% in either treatment arm).

Table 1: Adverse Reactions Reported in 2 or More Adult UCD Patients (at least 4% in Either Treatment Arm) in Study 1

| | Number (%) of Patients in Study 1 | |
|----------|-----------------------------------|---------------------|
| | Sodium Phenylbutyrate (N = 45) | RAVICTI (N = 44) |
| Diarrhea | 3 (7) | 7 (16) |

Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.